Pfizer (NYSE:PFE) posted a stronger-than-expected set of Q3 2022 results. Although revenue declined by about 6% versus last year to $22.6 billion, it came in ahead of estimates. Adjusted earnings stood at $1.78 per share, up 40% versus last year.
- What To Expect From Pfizer’s Q4?
- Is Pfizer Stock A Better Pick Over This Pharmaceuticals Bellwether?
- Should You Buy Pfizer Stock Ahead of Its Q3 Results?
- Pfizer’s Peer Appears To Be A Better Pharmaceuticals Pick
- Should You Buy Pfizer Stock After An Upbeat Q2?
- Should You Buy Pfizer Stock Ahead of Its Q2 Results?
While sales were weighed down by lower Covid-19 vaccine sales, this was partly offset by strong sales of Pfizer’s antiviral drug Paxlovid as well as Prevnar and Eliquis.
PFE stock was up by about 3% in Tuesday’s trading.
|S&P 500 Return||0%||-19%||72%|
|Trefis Multi-Strategy Portfolio||0%||-22%||208%|
 Month-to-date and year-to-date as of 11/2/2022
 Cumulative total returns since the end of 2016